Publications by authors named "C Tarella"
Richter syndrome (RS) represents a major unmet need in the lymphoma field, being refractory to chemoimmunotherapy and targeted agents. The BCL-2 inhibitor venetoclax in combination with dose-adjusted EPOCH-R chemoimmunotherapy showed promising efficacy in patients affected by RS. However, responses were not durable, suggesting the need for further treatment optimization.
View Article and Find Full Text PDFBackground: Myeloid neoplasms, including acute myeloid leukemia, have been traditionally among the less investigated cancer types concerning germline predisposition. Indeed, myeloid neoplasms with germline predisposition are challenging to identify because often display similar clinical and morphological characteristics of sporadic cases and have similar age at diagnosis. However, a misidentifications of familiarity in myeloid neoplasms have a critical impact on clinical management both for the carriers and their relatives.
View Article and Find Full Text PDFArticle Synopsis
- Acute myeloid leukemia (AML) remains difficult to treat despite new therapies, highlighting the need for effective immune responses against the disease.
- The review emphasizes various immunotherapy targets, including both cancer cell features and the surrounding environment, and suggests personalized treatment strategies.
- Key immunotherapy methods discussed include immune checkpoint inhibitors, antibody-drug conjugates, therapeutic vaccines, and CAR-T/NK cells, while also addressing resistance mechanisms and the impact of the leukemia microenvironment on treatment outcomes.
Data on the efficacy of high-dose chemotherapy and autologous stem cell transplantation (ASCT) for classical Hodgkin lymphoma (cHL) patients who failed a PET-driven first-line therapy are limited.We retrospectively evaluated 220 adult cHL patients who underwent ASCT from 2009 to 2021 at 11 centers in Italy. Overall, 49.
View Article and Find Full Text PDF